

Miguel A Frias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/901782/publications.pdf>

Version: 2024-02-01

31
papers

925
citations

516561

16
h-index

454834

30
g-index

31
all docs

31
docs citations

31
times ranked

1409
citing authors

#	ARTICLE	IF	CITATIONS
1	Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate. <i>Cardiovascular Research</i> , 2009, 82, 313-323.	1.8	90
2	Interplay Between SAFE and RISK Pathways in Sphingosine-1-Phosphate-Induced Cardioprotection. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 227-237.	1.3	77
3	Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. <i>Cardiovascular Research</i> , 2010, 85, 118-126.	1.8	67
4	Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. <i>Cardiovascular Research</i> , 2007, 73, 57-65.	1.8	66
5	HDLs Protect Pancreatic β -Cells Against ER Stress by Restoring Protein Folding and Trafficking. <i>Diabetes</i> , 2012, 61, 1100-1111.	0.3	63
6	Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 817-824.	1.1	61
7	Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43. <i>Cardiovascular Research</i> , 2016, 109, 385-396.	1.8	55
8	Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution. <i>Lipids in Health and Disease</i> , 2016, 15, 92.	1.2	47
9	Pharmacological Intervention to Modulate HDL: What Do We Target?. <i>Frontiers in Pharmacology</i> , 2017, 8, 989.	1.6	47
10	HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. <i>Atherosclerosis</i> , 2013, 228, 110-116.	0.4	42
11	Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury. <i>PLoS ONE</i> , 2015, 10, e0119664.	1.1	40
12	Therapeutic Potential of HDL in Cardioprotection and Tissue Repair. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 527-565.	0.9	39
13	The natural cardioprotective particle HDL modulates connexin43 gap junction channels. <i>Cardiovascular Research</i> , 2012, 93, 41-49.	1.8	37
14	The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis. <i>Cardiovascular Research</i> , 2008, 80, 69-77.	1.8	28
15	High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection. <i>Jak-stat</i> , 2012, 1, 92-100.	2.2	24
16	CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. <i>Endocrinology</i> , 2015, 156, 4707-4719.	1.4	20
17	JAK-STAT signaling and myocardial glucose metabolism. <i>Jak-stat</i> , 2013, 2, e26458.	2.2	18
18	HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3. <i>PLoS ONE</i> , 2019, 14, e0218432.	1.1	18

#	ARTICLE	IF	CITATIONS
19	High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12866.	1.7	16
20	High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154141.	1.5	11
21	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. <i>Journal of Clinical Medicine</i> , 2019, 8, 2035.	1.0	10
22	Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?. <i>Current Pharmaceutical Design</i> , 2019, 25, 3128-3146.	0.9	10
23	Abca1 deficiency protects the heart against myocardial infarction-induced injury. <i>Atherosclerosis</i> , 2016, 251, 159-163.	0.4	8
24	Impact of long distance rowing on biological health: A pilot study. <i>Clinical Biochemistry</i> , 2018, 52, 142-147.	0.8	7
25	HIV-related cardiovascular disease: any role for high-density lipoproteins?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H1221-H1226.	1.5	6
26	Prostacyclin production in rat aortic smooth muscle cells: role of protein kinase C, phospholipase D and cyclooxygenase-2 expression. <i>Cardiovascular Research</i> , 2003, 60, 438-446.	1.8	5
27	ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1. <i>Journal of Immunological Methods</i> , 2019, 469, 33-41.	0.6	5
28	High Density Lipoproteins and Ischemia Reperfusion Injury: The Therapeutic Potential of HDL to Modulate Cell Survival Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2014, 824, 19-26.	0.8	4
29	High-density lipoprotein-associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia. <i>European Journal of Clinical Investigation</i> , 2017, 47, 38-43.	1.7	3
30	Sphingosine-1-phosphate as a key player of insulin secretion induced by high-density lipoprotein treatment. <i>Physiological Reports</i> , 2021, 9, e14786.	0.7	1
31	Auto-antibodies against apolipoprotein A-1 block cancer cells proliferation and induce apoptosis. <i>Oncotarget</i> , 2020, 11, 4266-4280.	0.8	0